Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enterome Raises EUR Five Million in Series A Funding Round

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world population.

Enterome has announced a first closing of a series A funding round, raising EUR five million. This funding follows a previous seed round that raised EUR 1.5 million from Seventure Partners (Natixis) and INRA Transfert.

The series A round has brought in Seventure and Lundbeckfond Ventures, as new co-lead investors. Seventure is one of the most active European investors in venture capital investing in life sciences and information and communication technologies.

Lundbeckfond Ventures is a pure life science venture fund investing in companies in Europe and the US.

The amount raised will enable Enterome to fulfil several objectives. Firstly, Enterome will validate its proprietary biomarkers and translate them into high value medical diagnostics and to commercialize it as laboratory developed test services in the US and EU.

The company also plans to initiate industrial partnerships (in the pharmaceutical and the nutrition fields) to strengthen its development capabilities.

Enterome’s two lead projects are in non-alcoholic fatty liver disease (NAFLD) and in inflammatory bowel diseases (IBD).

The new management team is highly experienced and made up of a blend of former founders and executives of Fovea Pharmaceuticals (acquired by Sanofi in 2009) and biomarkers specialists. Bernard Gilly was also appointed as the new chairman of the board.

“The series A round investors - Seventure and Lundbeckfond Ventures - were specifically attracted to Enterome due to the unique nature of its technology, the close relationship to INRA and the opportunity to create unique biomarker diagnostic products meeting unmet medical and market needs,” said Pierre Belichard, CEO, Enterome.

Belichard continued, “Research by Enterome’s scientific founders has improved understanding of the human microbiota composition to the point of now allowing development of powerful new biomarkers and associated therapeutics. This technology was elected as one of top five scientific breakthroughs of 2011 by the journal Science.”

The human intestine harbors an incredible number of bacteria, the gut microbiota, encoding 150-fold more genes than the human genome. Each individual has his own personal and unique microbiota, with a large diversity between individuals.

Over the last five years, physicians and researchers have proved the undisputed role of gut microbiota in the development of various diseases, especially metabolic disorders and inflammatory bowel diseases.

These diseases affect 25 per cent of the western world population, with NASH, the most harmful, diagnosed in two to three per cent of the population globally.

Enterome’s technology was developed initially at the INRA (Institut National de la Recherche Agronomique) by Dusko Ehrlich at Jouy-en-Josas, France.

Enterome has entered into a collaboration agreement with INRA, providing the company with exclusive access to discoveries made using this metagenomic platform in selected human pathologies including type II diabetes, liver and bowel diseases.

“Measurement and modulation of the gut microbiota’s role in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way,” said Dusko Ehrlich, scientific founder of Enterome and leader of the metaHIT European consortium.

“We are particularly pleased to see one of our main research assets being translated into a company and financed by an international group of investors,” said Gérard Jacquin, president of INRA Technology Transfer organization. “Enterome is a key element in our Metagenopolis organization, a center for excellence in metagenomics of the human gut microbiota developed at INRA.”

“I am particularly proud to see Enterome developing, helped by the strong and longstanding relationship Seventure has established with INRA,” said Isabelle de Cremoux, CEO of Seventure subsidiary of Natixis.

“We are impressed by the Enterome leadership and are very confident that Enterome will translate this very innovative platform into valuable diagnostic and therapeutic tools,” said Johan Kordel from Lundbeckfond Ventures.

Emmanuelle Porte and Sylvie Hamel, specializing in venture capital and private equity at Nixon Peabody, acted as legal advisors for Enterome in this series A funding round.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!